SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 6 — Focused Visit (Care-plan review) — Wilma Mankiller

PatientWilma Mankiller
Date of birth1991-11-18
IdentifiersMRN HR-ML052-SYN; SSN (made up) 000-52-4183
Document date2026-10-12
AuthorRena Hawkfeather-Lindqvist, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Seven-month review. [S]

History of Present Illness

Ms. Mankiller returns seven months after her diagnosis. She has had no drooping eyelids, double vision or trouble chewing since the summer; only after a very long day does she feel her arms tire. Prednisone is now 15 mg each morning, and she stopped trimethoprim-sulfamethoxazole when the dose fell below 20 mg last week, as planned. She takes azathioprine 150 mg daily; the blood tests at the Cherokee Nation clinic two and six weeks after the dose increase were normal and the nurse called her each time. She has returned to full-time work. She sleeps better on the lower prednisone dose. Home blood pressure readings average 116/74. She drinks about 2.5 liters of water a day and has had no flank pain or blood in the urine. She would like fewer pyridostigmine tablets. [S]

ElementDetail
StrengthMG-ADL 1: minimal manifestation status
MedicinesPrednisone 15 mg; azathioprine 150 mg; pyridostigmine 60 mg four times daily; trimethoprim-sulfamethoxazole stopped
WorkFull time
KidneysHome blood pressure about 116/74; no symptoms

Review of Systems

SystemResultFinding
EyesNegativeNo ptosis or double vision
MusculoskeletalPositiveArms tire only after very long days
GenitourinaryNegativeNo flank pain or blood in the urine
ConstitutionalNegativeNo fever or infections; weight down 1 kg
PsychiatricNegativeMood good; sleeping better; PHQ-2 score 0

5 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Pyridostigmine bromide 30 mg oral tablet, one tablet three times daily with meals as a trial; take 30 to 45 minutes before eatingOne tablet three times dailyOral route2026-03-09 to 2026-03-23completedS
Pyridostigmine bromide 60 mg oral tablet, one tablet four times daily while awake, 30 to 45 minutes before mealsOne tablet four times daily while awakeOral route2026-03-23 to 2026-10-12completedS
Pyridostigmine bromide 60 mg oral tablet, one tablet three times daily, 30 to 45 minutes before mealsOne tablet three times dailyOral route2026-10-12activeS
Prednisone 10 mg oral tablet, 10 mg each morning, rising by 10 mg each week to 40 mg each morning, then held at 40 mgOnce each morning; dose as directedOral route2026-03-23 to 2026-07-13completedS
Prednisone 5 mg oral tablet, tapering from 40 mg each morning by 5 mg every two to three weeksOnce each morning; dose as directedOral route2026-07-13activeS
Azathioprine 50 mg oral tablet, one tablet daily for two weeks, then two tablets daily, then three tablets (150 mg, about 2.3 mg/kg) dailyOnce daily; dose as directedOral route2026-05-04activeS
Calcium carbonate 1250 mg (500 mg elemental calcium) oral tablet, one tablet daily with foodOne tablet daily with foodOral route2026-03-23activeS
Cholecalciferol (vitamin D3) 1000 units (0.025 mg) oral tablet, one tablet dailyOne tablet dailyOral route2026-03-23activeS
Sulfamethoxazole 800 mg / trimethoprim 160 mg oral tablet, one tablet three times a week, while prednisone is 20 mg or more with azathioprineOne tablet on Monday, Wednesday and FridayOral route2026-05-04 to 2026-10-05completedS
Acetaminophen 500 mg oral tablet, one or two tablets up to three times daily as needed for leg painOne or two tablets up to three times daily as neededOral route2025-09-15activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-10-12Body height163cmS
2026-10-12Body weight63.6kgS
2026-10-12Body mass index (BMI) [Ratio]23.9kg/m2S
2026-10-12Systolic blood pressure118mm[Hg]S
2026-10-12Diastolic blood pressure76mm[Hg]S
2026-10-12Heart rate72/minS
2026-10-12Respiratory rate14/minS
2026-10-12Body temperature36.6CelS
2026-10-12Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-10-12Hemoglobin [Mass/volume] in Blood12.9g/dL11.6-15 g/dLNormalS
2026-10-12Leukocytes [#/volume] in Blood by Automated count5.410*3/uL4-11 10*3/uLNormalS
2026-10-12Platelets [#/volume] in Blood by Automated count23810*3/uL150-400 10*3/uLNormalS
2026-10-12Creatinine [Mass/volume] in Serum or Plasma0.8mg/dL0.59-1.04 mg/dLNormalS
2026-10-12Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M99mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-10-12Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma23U/L7-45 U/LNormalS
2026-10-12Hemoglobin A1c/Hemoglobin.total in Blood5.6%<=5.6%NormalS
2026-10-12Albumin/Creatinine [Mass Ratio] in Urine16mg/gBelow 30 mg/g is normal (A1)NormalS
2026-10-12Forced vital capacity [Volume] Respiratory system3.62LLower limit of normal about 2.9 L for her age, sex and heightNormalS
2026-10-12Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]0{score}S

Physical Exam

Vital signs recorded on 2026-10-12; see the Vital Signs section. [S]

SystemFinding
GeneralWell; blood pressure 118/76 mm Hg; weight 63.6 kg
EyesNo ptosis after one minute of upgaze; no diplopia
NeurologicalStrength 5 of 5 without fatigue; speech normal
AbdomenBoth kidneys palpable, non-tender

Problems

ProblemClinical statusVerificationCodeProvenance
Drooping eyelids and double vision for six weeks, worse in the evening, with fatigable weakness of the arms and neck, tiring when chewing and a nasal voice after long talks; a disorder of the neuromuscular junction suspectedresolvedconfirmed H53.2S — Synthetic presenting problem, resolved at the second visit when antibodies and nerve testing established myasthenia gravis.
Generalized myasthenia gravis, acetylcholine receptor antibody positive, MGFA class IIa, without thymoma; synthetic modern detail linked to her documented myasthenia gravis of 1980activeconfirmed G70.00S — Synthetic antibody level, electrodiagnosis, class and treatment; the diagnosis less than a year after the crash, and recovery with Cherokee medicine people, surgery and drug therapy, are documented (D).
Autosomal dominant polycystic kidney disease (hereditary, as she has described it), with normal kidney function; to be stagedactiveconfirmed Q61.2S — The hereditary polycystic kidney disease is documented (D) from her later public account; its detection before the index date, and every value, are synthetic.
Recovery from major trauma in a head-on car crash last year: fractures of both legs, ribs and face, with many operations; walks independently, with a cane on rough groundactiveconfirmed Z87.81S — The crash, the operations and the injuries are documented (D); the current function is synthetic.
Long-term glucocorticoid therapy for myasthenia gravis, with monitoring of glucose, blood pressure, weight, bone health, mood, sleep, eyes and infectionactiveconfirmed Z79.52S — Synthetic treatment plan.
Azathioprine as steroid-sparing therapy, with blood count and liver test monitoringactiveconfirmed Z79.624S — Synthetic treatment plan.
Acquired absence of the thymus after robotic extended thymectomy for myasthenia gravis (pathology: thymic follicular hyperplasia, no thymoma)activeconfirmed Z90.89S — Synthetic: recorded after the thymectomy; the sources name surgery among her treatments without saying which.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
SurveyMG-ADL score and post-intervention statusEvery visitCompleted today1; minimal manifestation status
ImagingForced vital capacityEvery visit while on dose changesCompleted today3.62 L
LaboratoryBlood count on azathioprineEvery three months after the first two monthsCompleted todayHemoglobin 12.9 g/dL; white cells 5.4; platelets 238
LaboratoryLiver tests and creatinine on azathioprineEvery three monthsCompleted todayALT 23 U/L; creatinine 0.80 mg/dL; eGFR 99
LaboratoryHemoglobin A1c on glucocorticoidsPeriodicallyCompleted today5.6 percent
LaboratoryUrine albumin-to-creatinine ratioYearly in ADPKDCompleted today16 mg/g
ExaminationBlood pressureEvery visitCompleted today118/76 mm Hg in clinic; home average 116/74
ImagingBone density (DXA)Every one to three years on glucocorticoids by riskUp to dateNormal five months ago; repeat if glucocorticoids continue beyond a year
ExaminationEye examination on glucocorticoidsYearlyOrderedBooked next month at the Cherokee Nation eye clinic
Medication safetyPneumocystis prophylaxisWhile prednisone is 20 mg or more with azathioprineNot indicatedStopped last week when prednisone fell below 20 mg
Medication safetyMedicines that can worsen myasthenia gravisWith every new prescriptionCompleted todayNone prescribed; the list reviewed
Medication safetyVaccines on immunosuppressionSeasonalCompleted todayInactivated influenza and COVID-19 vaccines today
SurveyDepression screen (PHQ-2)At intervalsCompleted todayPHQ-2 score 0
Self-managementWater intake, salt, home blood pressure and laboratory accessEvery visitCompleted todayAbout 2.5 liters a day; home readings monthly; standing orders at the Cherokee Nation clinic working

Goal progress:

Immunizations given today: Inactivated influenza vaccine, this season; COVID-19 vaccine, mRNA, this season [S]

Guideline basis: Narayanaswami P, et al. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology 2021;96(3):114-122 (2020); Sanders DB, et al. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology 2016;87(4):419-425 (2016); KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). Kidney Int 2025;107(2S):S1-S239 (2025); Humphrey MB, et al. 2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol 2023;75(12):2088-2102 (2022)

Follow-up: Blood count and liver tests every three months at the Cherokee Nation clinic. Eye examination next month. Neuromuscular neurology in three months. Review here in three months. [S]